Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis

Cheng Chi Chao, Shi Juan Chen, Iannis Adamopoulos, Nicole Davis, Kyu Hong, Anna Vu, Sylvia Kwan, Laurence Fayadat-Dilman, Agelio Asio, Edward P. Bowman

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Interleukin-17A (IL-17A) is a pro-inflammatory cytokine secreted by a subset of memory T cells and other innate immune cells. It is associated with rheumatoid arthritis (RA) due to IL-17A expression in RA synovial fluid. The severe bone erosive rat adjuvant-induced arthritis (rAIA) and mouse collagen-induced arthritis (mCIA) models were used to address the therapeutic efficacy of anti-IL-17A treatment with a focused investigation on bone protection. In the rAIA model, treatment with anti-IL-17A completely alleviated arthritis, lowered the level of receptor activator of NFκB ligand (RANKL), and inhibited structural damage to the bones. In the mCIA model, IL-17A neutralization coincident with arthritis development or in mice with established arthritis diminished joint swelling by inhibiting disease initiation and progression. Intriguingly, even the few joints that became outwardly severely inflamed in the presence of an anti-IL-17A antagonist had diminished joint histopathology scores compared to severely inflamed, control-treated mice. The bone-preserving property correlated with decreased RANKL message in severely inflamed paws of arthritic mice. These data identify IL-17A as a key factor in inflammation-mediated bone destruction and support anti-IL-17A therapy for the treatment of inflammatory bone diseases such as RA.

Original languageEnglish (US)
Pages (from-to)243-252
Number of pages10
JournalAutoimmunity
Volume44
Issue number3
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Interleukin-17
Rheumatoid Arthritis
Theoretical Models
Bone and Bones
Experimental Arthritis
Arthritis
Joints
Therapeutics
Osteitis
Bone Diseases
Synovial Fluid
T-Lymphocyte Subsets
Disease Progression
Cytokines
Ligands

Keywords

  • adjuvant-induced arthritis
  • collagen-induced arthritis
  • IL-17A
  • inflammation
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. / Chao, Cheng Chi; Chen, Shi Juan; Adamopoulos, Iannis; Davis, Nicole; Hong, Kyu; Vu, Anna; Kwan, Sylvia; Fayadat-Dilman, Laurence; Asio, Agelio; Bowman, Edward P.

In: Autoimmunity, Vol. 44, No. 3, 05.2011, p. 243-252.

Research output: Contribution to journalArticle

Chao, CC, Chen, SJ, Adamopoulos, I, Davis, N, Hong, K, Vu, A, Kwan, S, Fayadat-Dilman, L, Asio, A & Bowman, EP 2011, 'Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis', Autoimmunity, vol. 44, no. 3, pp. 243-252. https://doi.org/10.3109/08916934.2010.517815
Chao, Cheng Chi ; Chen, Shi Juan ; Adamopoulos, Iannis ; Davis, Nicole ; Hong, Kyu ; Vu, Anna ; Kwan, Sylvia ; Fayadat-Dilman, Laurence ; Asio, Agelio ; Bowman, Edward P. / Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. In: Autoimmunity. 2011 ; Vol. 44, No. 3. pp. 243-252.
@article{ff3e8345f8fb4e08a3d64ff139be0c99,
title = "Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis",
abstract = "Interleukin-17A (IL-17A) is a pro-inflammatory cytokine secreted by a subset of memory T cells and other innate immune cells. It is associated with rheumatoid arthritis (RA) due to IL-17A expression in RA synovial fluid. The severe bone erosive rat adjuvant-induced arthritis (rAIA) and mouse collagen-induced arthritis (mCIA) models were used to address the therapeutic efficacy of anti-IL-17A treatment with a focused investigation on bone protection. In the rAIA model, treatment with anti-IL-17A completely alleviated arthritis, lowered the level of receptor activator of NFκB ligand (RANKL), and inhibited structural damage to the bones. In the mCIA model, IL-17A neutralization coincident with arthritis development or in mice with established arthritis diminished joint swelling by inhibiting disease initiation and progression. Intriguingly, even the few joints that became outwardly severely inflamed in the presence of an anti-IL-17A antagonist had diminished joint histopathology scores compared to severely inflamed, control-treated mice. The bone-preserving property correlated with decreased RANKL message in severely inflamed paws of arthritic mice. These data identify IL-17A as a key factor in inflammation-mediated bone destruction and support anti-IL-17A therapy for the treatment of inflammatory bone diseases such as RA.",
keywords = "adjuvant-induced arthritis, collagen-induced arthritis, IL-17A, inflammation, rheumatoid arthritis",
author = "Chao, {Cheng Chi} and Chen, {Shi Juan} and Iannis Adamopoulos and Nicole Davis and Kyu Hong and Anna Vu and Sylvia Kwan and Laurence Fayadat-Dilman and Agelio Asio and Bowman, {Edward P.}",
year = "2011",
month = "5",
doi = "10.3109/08916934.2010.517815",
language = "English (US)",
volume = "44",
pages = "243--252",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis

AU - Chao, Cheng Chi

AU - Chen, Shi Juan

AU - Adamopoulos, Iannis

AU - Davis, Nicole

AU - Hong, Kyu

AU - Vu, Anna

AU - Kwan, Sylvia

AU - Fayadat-Dilman, Laurence

AU - Asio, Agelio

AU - Bowman, Edward P.

PY - 2011/5

Y1 - 2011/5

N2 - Interleukin-17A (IL-17A) is a pro-inflammatory cytokine secreted by a subset of memory T cells and other innate immune cells. It is associated with rheumatoid arthritis (RA) due to IL-17A expression in RA synovial fluid. The severe bone erosive rat adjuvant-induced arthritis (rAIA) and mouse collagen-induced arthritis (mCIA) models were used to address the therapeutic efficacy of anti-IL-17A treatment with a focused investigation on bone protection. In the rAIA model, treatment with anti-IL-17A completely alleviated arthritis, lowered the level of receptor activator of NFκB ligand (RANKL), and inhibited structural damage to the bones. In the mCIA model, IL-17A neutralization coincident with arthritis development or in mice with established arthritis diminished joint swelling by inhibiting disease initiation and progression. Intriguingly, even the few joints that became outwardly severely inflamed in the presence of an anti-IL-17A antagonist had diminished joint histopathology scores compared to severely inflamed, control-treated mice. The bone-preserving property correlated with decreased RANKL message in severely inflamed paws of arthritic mice. These data identify IL-17A as a key factor in inflammation-mediated bone destruction and support anti-IL-17A therapy for the treatment of inflammatory bone diseases such as RA.

AB - Interleukin-17A (IL-17A) is a pro-inflammatory cytokine secreted by a subset of memory T cells and other innate immune cells. It is associated with rheumatoid arthritis (RA) due to IL-17A expression in RA synovial fluid. The severe bone erosive rat adjuvant-induced arthritis (rAIA) and mouse collagen-induced arthritis (mCIA) models were used to address the therapeutic efficacy of anti-IL-17A treatment with a focused investigation on bone protection. In the rAIA model, treatment with anti-IL-17A completely alleviated arthritis, lowered the level of receptor activator of NFκB ligand (RANKL), and inhibited structural damage to the bones. In the mCIA model, IL-17A neutralization coincident with arthritis development or in mice with established arthritis diminished joint swelling by inhibiting disease initiation and progression. Intriguingly, even the few joints that became outwardly severely inflamed in the presence of an anti-IL-17A antagonist had diminished joint histopathology scores compared to severely inflamed, control-treated mice. The bone-preserving property correlated with decreased RANKL message in severely inflamed paws of arthritic mice. These data identify IL-17A as a key factor in inflammation-mediated bone destruction and support anti-IL-17A therapy for the treatment of inflammatory bone diseases such as RA.

KW - adjuvant-induced arthritis

KW - collagen-induced arthritis

KW - IL-17A

KW - inflammation

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=79953073305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953073305&partnerID=8YFLogxK

U2 - 10.3109/08916934.2010.517815

DO - 10.3109/08916934.2010.517815

M3 - Article

C2 - 20925596

AN - SCOPUS:79953073305

VL - 44

SP - 243

EP - 252

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 3

ER -